01. Doctor Overview
Dr. Thierry Marie Jahan is a former lung cancer specialist and Clinical Professor of Medicine at the University of California San Francisco (UCSF). Dr. Jahan retired from his position in 2021.
Dr. Jahan is a graduate of George Washington University School of Medicine in Washington, D.C. Dr. Jahan was affiliated with the UCSF Medical Center, where he specialized in treating lung disease, lung cancers and mesothelioma.
He is the recipient of a number of awards for both his academic and scientific work. Before retiring, Dr. Jahan authored and co-authored many academic publications. During his career, he served as Bonnie J. and Anthony Addario Endowed Chair in Thoracic Oncology at UCSF. Dr. Jahan also worked at UCSF as a Clinical Professor of Medicine.
For many years, Dr. Jahan was dedicated to the treatment of mesothelioma, lung cancer, sarcomas and endocrine tumors with multiple treatment options. He also specialized in the study of new treatments for malignancies related to the chest while continuing to care for his patients. His interests included new, state-of-the-art molecular analyses and specifically designed drugs that target the disease precisely. These drugs may result in far fewer side effects, improved quality of life and longer life expectancy for those suffering with lung cancer and mesothelioma.
02. Fast Facts
Doctor Fast Facts
Former Specialty: Oncology
Other Interests & Specialties: General oncology, mesothelioma, non-small cell lung cancer, chest wall tumors, multimodal therapy, endocrine cancer, hematologic oncology, sarcoma and thoracic cancer.
Certifications, Awards & Accolades: American Board of Internal Medicine Certification in Medical Oncology, American Board of Internal Medicine Certification in Internal Medicine, American Board of Internal Medicine Certification in Hematology, inducted into the Council of Master Clinicians by the UCSF Department of Medicine, Medical House Staff Outstanding Teacher Award, Friend of the Palliative Care Service Award, member of American Society of Clinical Oncology (ASCO), International Association for the Study of Lung Cancer (IASLC), Association of Northern California Oncologists and the UCSF Helen Diller Family Comprehensive Cancer Center
Education & Experience:
- Residency in Internal Medicine at Cedars-Sinai Medical Center
- Fellowship in Hematology/Oncology at UCSF
- Fellowship in Internal Medicine at Cedars-Sinai Medical Center
- Medical Degree from George Washington University School of Medicine
Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology. May 2018;36(13):1343-1373. doi: 10.1200/JCO.2017.76.6394
Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma. Clinical Cancer Research. December 2014;20(23):5927-5936. doi: 10.1158/1078-0432
Vatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107). Lung Cancer. June 2012;76(3):393-396. doi: 10.1016/j.lungcan.2011.11.014
Implications of delayed initiation of radiotherapy: accelerated repopulation after induction chemotherapy for stage III non-small cell lung cancer. Journal of Thoracic Oncology. November 2011;6(11):1857-64. doi: 10.1097/JTO.0b013e318229a41e
Radical pleurectomy/decortication and intraoperative radiotherapy followed by conformal radiation with or without chemotherapy for malignant pleural mesothelioma. The Journal of Thoracic and Cardiovascular Surgery. December 2002;124(6):1183-1189. doi: 10.1067/mtc.2002.125817